The continuing interference proceedings in the US concerning clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 systems for gene-editing of eukaryotes have received much media attention. Coverage focuses on two groups: one led by Feng Zhang of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, and the other by Jennifer Doudna of the University of California, Berkeley and Emmanuelle Charpentier of the Helmholtz Centre for Infection Research. The commentary focuses on a potential winner-takes-all scenario.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 September 2017 Feng Zhang, one of the pioneers of CRISPR technology, has been announced as the 2017 recipient of the $500,000 Lemelson-MIT Prize, which honours outstanding inventors.
20 September 2017 Feng Zhang, one of the pioneers of CRISPR technology, has been announced as the 2017 recipient of the $500,000 Lemelson-MIT Prize, which honours outstanding inventors.
20 September 2017 Feng Zhang, one of the pioneers of CRISPR technology, has been announced as the 2017 recipient of the $500,000 Lemelson-MIT Prize, which honours outstanding inventors.